Insulet - PODD Stock Forecast, Price & News

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PODD. Piper Sandler upped their target price on Insulet from $230.00 to $235.00 and gave the stock a "neutral" rating in a research report on Friday, August 5th. BTIG Research increased their price objective on shares of Insulet to $285.00 in a research report on Tuesday, August 9th. Raymond James boosted their target price on shares of Insulet from $262.00 to $280.00 in a research report on Friday, August 5th. Citigroup raised their price target on shares of Insulet to $260.00 in a report on Tuesday, August 9th. Finally, Robert W. Baird boosted their price objective on shares of Insulet from $245.00 to $300.00 and gave the stock an "outperform" rating in a report on Friday, August 5th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $295.23.

Insulet Stock Down 0.8 %

Insulet stock traded down $2.03 during midday trading on Tuesday, hitting $268.61. The stock had a trading volume of 326,395 shares, compared to its average volume of 564,032. The business has a fifty day moving average price of $233.93 and a 200 day moving average price of $238.18. Insulet has a 12 month low of $181.00 and a 12 month high of $324.81. The stock has a market cap of $18.64 billion, a P/E ratio of 537.22 and a beta of 0.73. The company has a current ratio of 4.69, a quick ratio of 3.54 and a debt-to-equity ratio of 3.28.

Insulet (NASDAQ:PODD - Get Rating) last issued its earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.50) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.72). Insulet had a return on equity of 13.83% and a net margin of 2.94%. The firm had revenue of $299.40 million during the quarter, compared to analyst estimates of $290.87 million. During the same quarter in the previous year, the business posted $0.10 EPS. Insulet's revenue was up 13.8% compared to the same quarter last year. Research analysts predict that Insulet will post 0.87 EPS for the current year.

Insiders Place Their Bets

In other news, COO Charles Alpuche sold 6,000 shares of Insulet stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $215.32, for a total value of $1,291,920.00. Following the completion of the transaction, the chief operating officer now directly owns 43,899 shares of the company's stock, valued at approximately $9,452,332.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, COO Charles Alpuche sold 6,000 shares of the stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $215.32, for a total transaction of $1,291,920.00. Following the sale, the chief operating officer now directly owns 43,899 shares in the company, valued at approximately $9,452,332.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Shacey Petrovic sold 15,000 shares of the business's stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $222.90, for a total value of $3,343,500.00. Following the transaction, the director now owns 13,695 shares of the company's stock, valued at approximately $3,052,615.50. The disclosure for this sale can be found here. 0.90% of the stock is owned by corporate insiders.